biostudies-literatureUnknown133(3)Cen RCenters for Disease Control and PreventionUniversity of North Carolina Clinical Nutrition Research CenterCDC HHS<h4>Objective</h4>To investigate associations between maternal periconceptional (three months prior through the third pregnancy month) myo-inositol intake and the odds of selected congenital heart defects in offspring.<h4>Design</h4>A population-based case-control study using the National Birth Defects Prevention Study (NBDPS) database.<h4>Setting</h4>United States.<h4>Population or sample</h4>Women with singleton live births without major birth defects (controls) and women with singleton live births, stillbirths, or terminations with selected nonsyndromic congenital heart defects (CHD; cases).<h4>Methods</h4>Descriptive analyses, logistic regression models, ascertainment of myo-inositol intake from supplements and food using a shortened food frequency questionnaire and survey.<h4>Main outcome measures</h4>Odds of CHD.<h4>Results</h4>11 752 cases and 11 415 controls were included. Compared to women not taking myo-inositol supplements, women with any supplemental intake were less likely to have a pregnancy with the selected congenital heart defects as a group (adjusted odds ratio [aOR] = 0.79; 95% confidence interval [CI] 0.66-0.94) or with septal defects alone (aOR = 0.61; 95% CI 0.46-0.81). Compared to women with low total myo-inositol intake from food or supplements, women with high total myo-inositol intake (≥ 500 mg/day) were less likely to have a pregnancy with the selected CHD as a group (aOR = 0.88; 95% CI 0.84-0.93) or conotruncal defects (aOR = 0.87; 95% CI 0.79-0.96); left ventricular outflow tract defects (aOR = 0.87; 95% CI 0.78-0.96); right ventricular outflow tract defects (aOR = 0.85; 95% CI 0.77-0.95); or atrial septal defects (aOR = 0.91; 95% CI 0.83-0.99).<h4>Conclusions</h4>An inverse association was observed between maternal myo-inositol intake during the periconceptional period and the odds of selected CHDs in offspring.BJOG : an international journal of obstetrics and gynaecology442-453https://www.ebi.ac.uk/biostudies/studies/S-EPMC12770076biostudies-literatureMaternal Myo-Inositol Intake and Congenital Heart Defects in Offspring: A Population-Based Case-Control Study.PMC12770076Cen RNembhard WNRomitti PAFinnell RHYing JLou XJenkins MMAlmli LMOlshan AFShaw GMNational Birth Defects Prevention StudyBolin EHNestoridi ESu LJOrloff MSBrowne MLBotto LDfalseMaternal Myo-Inositol Intake and Congenital Heart Defects in Offspring: A Population-Based Case-Control Study.<h4>Objective</h4>To investigate associations between maternal periconceptional (three months prior through the third pregnancy month) myo-inositol intake and the odds of selected congenital heart defects in offspring.<h4>Design</h4>A population-based case-control study using the National Birth Defects Prevention Study (NBDPS) database.<h4>Setting</h4>United States.<h4>Population or sample</h4>Women with singleton live births without major birth defects (controls) and women with singleton live births, stillbirths, or terminations with selected nonsyndromic congenital heart defects (CHD; cases).<h4>Methods</h4>Descriptive analyses, logistic regression models, ascertainment of myo-inositol intake from supplements and food using a shortened food frequency questionnaire and survey.<h4>Main outcome measures</h4>Odds of CHD.<h4>Results</h4>11 752 cases and 11 415 controls were included. Compared to women not taking myo-inositol supplements, women with any supplemental intake were less likely to have a pregnancy with the selected congenital heart defects as a group (adjusted odds ratio [aOR] = 0.79; 95% confidence interval [CI] 0.66-0.94) or with septal defects alone (aOR = 0.61; 95% CI 0.46-0.81). Compared to women with low total myo-inositol intake from food or supplements, women with high total myo-inositol intake (≥ 500 mg/day) were less likely to have a pregnancy with the selected CHD as a group (aOR = 0.88; 95% CI 0.84-0.93) or conotruncal defects (aOR = 0.87; 95% CI 0.79-0.96); left ventricular outflow tract defects (aOR = 0.87; 95% CI 0.78-0.96); right ventricular outflow tract defects (aOR = 0.85; 95% CI 0.77-0.95); or atrial septal defects (aOR = 0.91; 95% CI 0.83-0.99).<h4>Conclusions</h4>An inverse association was observed between maternal myo-inositol intake during the periconceptional period and the odds of selected CHDs in offspring.2026-01-01T00:00:00Z2026 Feb2026-06-11T03:09:52.648Z2026-06-11T03:07:50.27ZS-EPMC127700764130747610.1111/1471-0528.70045